Table 3.

Risk estimates of AAT use according to the income quintile with all-cause death as a competing event.

Outcome	Income quintile	Unadjusted SHR	Adjusted SHR
Any AAT	1st	(Reference)	(Reference)
	2nd	1.42 (1.37–1.47)	1.18 (1.43–1.23)
	3rd	1.50 (1.45–1.55)	1.25 (1.21–1.30)
	4th	1.67 (1.62–1.73)	1.35 (1.30–1.40)
	5th	1.91 (1.85–1.98)	1.49 (1.44–1.55)
AADs	1st	(Reference)	(Reference)
	2nd	1.50 (1.42–1.59)	1.24 (1.17–1.31)
	3rd	1.64 (1.55–1.74)	1.38 (1.30–1.46)
	4th	1.80 (1.71–1.91)	1.50 (1.41–1.58)
	5th	2.10 (1.99–2.21)	1.71 (1.61–1.82)
Cardioversion	1st	(Reference)	(Reference)
	2nd	1.40 (1.34–1.45)	1.17 (1.12–1.21)
	3rd	1.46 (1.40–1.51)	1.21 (1.17–1.26)
	4th	1.65 (1.59–1.72)	1.32 (1.27–1.37)
	5th	1.85 (1.78.1.92)	1.42 (1.36–1.48)
Catheter ablation	1st	(Reference)	(Reference)
	2nd	1.94 (1.72–2.20)	1.40 (1.24–1.59)
	3rd	2.31 (2.04–2.60)	1.62 (1.43–1.83)
	4th	2.74 (2.43–3.08)	1.76 (1.56–2.00)
	5th	3.41 (3.04–3.82)	2.02 (1.78–2.28)

Abbreviations: AAD, antiarrhythmic drug; AAT, antiarrhythmic therapy; SHR, subdistribution hazard ratio. 95% confidence intervals in parenthesis. SHRs estimated by Fine-Gray subdistribution hazard regression and adjusted for age, sex, calendar year of AF diagnosis, education level, dementia, cancer, alcohol use disorder, psychiatric disorders, prior stroke, abnormal liver function, abnormal kidney function, diabetes, hypertension, coronary heart disease and heart failure.